138 results about "Lymphocytic cell" patented technology

The purpose of the present invention is to provide a novel therapeutic agent or prophylactic agent for dry eye, a therapeutic agent or prophylactic agent for a graft-versus-host disease, a corneal epithelial wound healing promoter, an inflammatory cell inhibitor that infiltrates the cornea, a tear fluid amount retaining agent, a corneal epithelial disorder inhibitor, a cell proliferation marker-positive cell inhibitor, and an inhibitor of lymphocyte differentiation into effector T cells. The present invention provides the following, each of which contains, as an active ingredient, a substance derived from a culture supernatant of stem cells: a therapeutic agent or prophylactic agent for dry eye; a therapeutic agent or prophylactic agent for a graft-versus-host disease; a corneal epithelial wound healing promoter; an inflammatory cell inhibitor infiltrating into the cornea; a tear fluid amount retaining agent; a corneal epithelial disorder inhibitor; a cell proliferation marker-positive cell inhibitor; or an inhibitor of lymphocyte differentiation into effector T cells.

A biomarker for predicting drug resistance of a BTK inhibitor and an application thereof are provided in the present disclosure, relating to the technical field of biomedicine. The biomarker is SMPD1 or SPHK1; the drug resistance of BTK inhibitor refers to the drug resistance of diffuse large B cell lymphom cells to the BTK inhibitor. This biomarker is used to predict sensitivity of diffuse large B cell lymphom cells to the BTK inhibitors.

Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-LAG-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL).

The invention provides a probe library for high-throughput detection of mouse and hamster related species-specific viruses in a CHO cell library and application of the probe library. The probe library is used for detecting a mouse pox virus, a hantavirus, a K virus, a lactic dehydrogenase virus, a lymphocytic choriomeningitis virus, a mouse microvirus, a mouse adenovirus, a mouse cytomegalovirus, a mouse encephalomyelitis virus, a mouse hepatitis virus, a mouse rotavirus, a mouse pneumovirus, a multiple oma virus, a reovirus type 3 and a sendai virus; sV5 and thymoviruses and variant viruses thereof. The high-throughput sequencing method based on the probe library can be used for distinguishing viral nucleic acid with infection risk and quickly checking whether a sample is polluted by specific live viruses or not. The detection limit reaches the level of a traditional PCR method, the capability of detecting all known variants of to-be-detected species-specific viruses is kept, 17 viruses can be detected only by implementing one detection item, and the method has the advantages of high efficiency, rapidness and high sensitivity.

This application relates to the technical field of pharmaceutical preparations, and specifically discloses a pharmaceutical composition containing ibrutinib and its preparation method. The composition includes the active ingredient ibrutinib, colloidal silicon dioxide, solubilizers, and other excipients such as excipients; its preparation method is: the active ingredient ibrutinib is preferentially mixed with colloidal silicon dioxide and solubilizers, followed by dry granulation, mixing, and capsule filling. The composition of this application can be used for the treatment of diseases such as mantle cell lymphoma (MCL) / chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, etc. It can effectively break the insoluble complex salt formed by ibrutinib and solubilizers, and has the advantages of fast dissolution rate and significantly improved bioavailability; in addition, the preparation method of this application has the advantages of good process reproducibility, simple process steps, low production cost, and being suitable for large-scale industrial production.

The invention discloses an application of an ALK / LTK inhibitor in preparation of a product for treating and / or preventing chronic lymphocytic leukemia. Cell tests prove that the ALK / LTK inhibitor can inhibit an AKT signal channel at the downstream of LTK, so that the cell cycle of tumor cells is stopped, cell apoptosis is promoted, and finally the inhibiting effect on CLL cell proliferation is achieved; in a mouse model, the ALK / LTK inhibitor is proved to be capable of remarkably prolonging the survival time of tumor-bearing mice; the invention provides more drug choices for clinical treatment of CLL.

As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and / or for inclusion in a clinical trial using the agent to treat CLL.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a pharmaceutical composition containing ibrutinib and a preparation method of the pharmaceutical composition. The composition comprises an active component ibrutinib, colloidal silicon dioxide, a solubilizer, an excipient and other auxiliary materials. The preparation method comprises the following steps: preferentially mixing the active component ibrutinib with the colloidal silicon dioxide and the solubilizer, and carrying out dry granulation, mixing and capsule filling. The composition can be used for treating diseases such as mantle cell lymphoma (MCL) / chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, can effectively break insoluble double salt formed by ibrutinib and a solubilizer, and has the advantages of being high in dissolution rate and remarkably improving bioavailability; in addition, the preparation method has the advantages of being good in process reproducibility, simple in process step, low in production cost and suitable for large-scale industrial production.

A conjugate contains an amatoxin, a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking the amatoxin and said CD37-binding moiety, and the conjugate is prepared in a synthesis method. A pharmaceutical composition contains the conjugate for use in the treatment of immune cell-, particularly B-cell and / or lymphoma associated diseases and / or malignancies.

The present invention discloses the use of an inhibitor anti-CD90.2, which can reduce the expression of innate lymphoid cells and thus can be used as an anti-pneumonia preparation targeting ILC for post-infarct pneumonia. The expression of ILC2 cells in patients with acute cerebral infarction increases. After the clearance of ILC, differential expression of pneumonia-related indicators is observed in patients with acute cerebral infarction, indicating that ILC2 promotes pneumonia after cerebral infarction. The inhibitor anti-CD90.2 (250 μg / mouse) was injected into Rag- / - mice 48 hours before modeling. The expression of ILC2 was measured 24 hours after MCAO modeling and was found to decrease, indicating that the inhibitor anti-CD90.2 can play an anti-pneumonia role by reducing the expression of ILC2 in mice with acute cerebral infarction. The present invention provides a new target for the prevention and treatment of pneumonia, a complication after acute cerebral infarction surgery. At the same time, it is proposed that the inhibitor anti-CD90.2 reduces the expression of ILC2 and thus can be used as an anti-pneumonia preparation targeting ILC2, achieving an effective combination of theoretical research and practical application.

The invention provides a construction method and a construction system of a chronic lymphocytic leukemia prediction model based on machine learning, electronic equipment and a storage medium, and relates to the field of chronic lymphocytic leukemia prognosis research. The construction method comprises the steps of obtaining original sample data, and performing preliminary screening; performing data cleaning on the screened sample data; determining a prediction factor from the plurality of features of the cleaned sample data; dividing the cleaned sample data corresponding to the prediction factor and the target variable into a training set and a test set; inputting the training set after unbalance processing into a LightGBM model for training to obtain a prediction model; inputting the test set into a prediction model, performing hyper-parameter optimization on the prediction model, and evaluating the performance of the prediction model; calibrating the prediction model to obtain a calibrated prediction model; the method has the beneficial effects that the method can be realized only by depending on conventionally available predictive factors, and the patient screening can be realized before the CLL clinical symptoms appear.

To provide pharmaceutical combinations of anti-CD19 antibodies and Bruton's tyrosine kinase (BTK) for treating non-Hodgkin lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.SOLUTION: Disclosed is a synergistic combination of a CD19-specific antibody and a Bruton's tyrosine kinase (BTK) inhibitor, where the antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO:1), an HCDR2 region of sequence NPYNDG (SEQ ID NO:2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO:3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO:5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO:6), where the combination is used for treating non-Hodgkin lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.SELECTED DRAWING: None

The present application relates to the fields of bioengineering and technology, and specifically to a method for resuscitating and culturing ROBO1CAR NK cells. The method comprises: resuscitating and culturing the cells using a resuscitation medium, wherein the resuscitation medium is a serum-free HIPP-T009 lymphocyte culture medium containing IL-2 and nicotinamide; performing a primary amplification culture on the resuscitated cells using a first amplification culture medium to obtain primary amplified cells; and performing a secondary amplification culture on the primary amplified cells using a second amplification culture medium to harvest the cells. The method can rapidly resuscitate frozen cells, effectively maintain cell growth and cell killing activity, and expand the culture scale, greatly reducing the culture cycle and production costs.

Provided herein are methods of treating a subject having a CD20 - positive cell-proliferative disorder (e.g., a B-cell proliferative disorder, e.g., non-Hodgkin's lymphoma or chronic lymphocytic leukaemia).SOLUTION: The present invention provides the treatment of a subject having a B-cell proliferative disorder by subcutaneous administration of mosnetuzumab as monotherapy or in combination with lenalidomide.SELECTED DRAWING: Figure 10

Provided are DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, that bind to or target a target site in a gene or regulatory element thereof in a stem cell. In some embodiments, the provided DNA-targeting systems promote transcriptional activation of genes that promote lymphoid cell differentiation. In some embodiments, the provided DNA-targeting systems promote differentiation of hematopoietic progenitor cells (HPCs) into a differentiated population of cells. In some embodiments, the differentiated population of cells are lymphoid progenitor cells. In some embodiments, the differentiated population of cells are lymphoid cells. Also provided herein are methods and uses related to the provided compositions, for example in facilitating lymphoid cell differentiation without the provision of extrinsic differentiation signals.

This invention relates to the application of PGG in the preparation of drugs for treating acute leukemia, belonging to the field of biomedical technology. To address the problems of narrow application range and easy development of drug resistance in existing acute leukemia treatments, this invention provides the application of PGG in the preparation of drugs for treating acute leukemia. Experiments have shown that PGG can inhibit the viability, proliferation, and colony formation of human acute myeloid leukemia cells (MOLM-13) and human acute lymphoblastic leukemia cells (Jurkat), and induce their apoptosis. In animal models, intraperitoneal injection of PGG can prolong the survival days of mice with acute leukemia and reduce the infiltration of leukemia cells in the liver, spleen, and bone marrow tissues. In this invention, PGG directly inhibits the viability of acute leukemia cells and can simultaneously inhibit AML and ALL, without relying on specific gene mutations, resulting in a lower risk of drug resistance, more flexible clinical use, and broader patient coverage, showing promising clinical application prospects.

Epigenetically modified DNA targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, are provided that bind to or target one or more target sites in the IL-2 gene or its regulatory elements in cells such as lymphoid cells (e.g., T cells). In some embodiments, the provided epigenetically modified DNA targeting systems modulate the phenotype or activity of lymphoid cells, or the function of lymphoid cells such as the phenotype or activity of T cells. In some embodiments, methods and uses relating to the provided compositions in the modulation of lymphoid cells such as T cells are also provided, for example, in connection with adoptive T cell therapy.

The present disclosure provides methods of treating a human subject suffering from lung cancer (e.g., non-small cell lung cancer (NSCLC)) using a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and synchronous chemoradiotherapy (CCRT, e.g., platinum-based dual drug chemotherapy (PDCT) and radiotherapy), a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody) is then used. In some aspects, the methods include a recovery phase that begins after completion of treatment with a PD-1 pathway inhibitor and CCRT, and ends at the beginning of treatment with a combination of a PD-1 pathway inhibitor and a LAG-3 antagonist.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

Provided are methods for treating a subject of a solid tumor expressing GPC3 comprising administering to the subject an anti-GPC3 chimeric antigen receptor immunoresponsive cell wherein the administering is performed after or concurrently with subjecting the subject to a lymphopenia treatment. A kit for use in the method is also provided.

The invention relates to the technical field of dendritic cell in-vitro induction methods, and provides a dendritic cell body and an in-vitro induction method and application thereof. Thymic stromal lymphopoietin; the invention relates to a recombinant human FLT3L-Fc fusion protein. And maturing stimulation combination. On the premise of avoiding complex use of equipment, the bottlenecks of DC yield, subgroup purity and functionality are broken through.

To provide a separation agent for RNA with a 5' cap structure or the like, enabling the efficient and economical separation of RNA with a 5' cap structure.SOLUTION: The present invention provides a separation agent for RNA with a 5' cap structure or the like in which the terminal unit is a 7-methylguanylic acid residue, where the agent comprises a compound represented by formula (I): A-L-R1 (I) (where A represents a separation carrier residue with a reactive functional group, L represents a linker, and R1 represents a group that reacts with the 7-methylguanine moiety of 7-methylguanosine to form a protecting group).SELECTED DRAWING: None

The present disclosure relates to CD19 / 22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haematological malignancies.

The present invention relates to the field of cell therapy, and specifically relates to a method for preparing a CAR-expressing T cell and a use. Disclosed in the present invention is a method for preparing a CAR-T cell, comprising the following steps: S1, collecting a T cell-containing cell population of an autologous or allogeneic donor of a subject; S2, administering lymphodepletion therapy to the subject for pretreatment; and S3, administering the T cell-containing cell population and a viral vector to the subject.

The present invention provides the use of isogaminol compounds in combination with glucocorticoids in the preparation of a leukemia treatment drug, belonging to the technical fields of biology and medicine. The isogaminol compounds described herein, when used in combination with glucocorticoids, can enhance the sensitivity of Jurkat cells to glucocorticoids, induce G1 cell cycle arrest in Jurkat cells, and induce apoptosis in Jurkat cells. The combined use of isogaminol compounds and glucocorticoids in the present invention provides a research foundation for overcoming glucocorticoid resistance in acute lymphoblastic leukemia.

The invention belongs to the technical field of virus infection cell lines, and particularly relates to a rats kidney cell line and application thereof. Wherein the preservation number of the kidney cell line of the rats with the yellow chest is CCTCC (China Center For Type Culture Collection) NO: C2025271. The rats kidney cell line (RtK-15W) provided by the invention has multiple advantages of high sensitivity, high replication efficiency, quantitative detection, passage stability and the like on arenavirus; a reliable cell tool and an efficient, reliable and generalizable experimental platform are provided for separation and identification, in-vitro amplification, titer determination, pathogenesis research, drug screening, antibody neutralization experiment, vaccine effect evaluation and the like of arenaviruses (including lymphocytic choriomeningitis virus (LCMV) and Wenzhou virus (WENV)).

The method (400) includes receiving an input tissue structure image (110), generating one or more lymphocyte density maps (125) inside the input tissue structure image by processing the input tissue structure image using a cell classification model (550), and identifying one or more TLS regions (135) inside the input tissue structure image by performing morphological image processing (130) on the one or more lymphocyte density maps. Each TLS region is represented by each cluster of lymphocyte cells. For each corresponding TLS region of the one or more TLS regions identified in the input tissue structure image, the method includes extracting each set of TLS features (140) from each cluster of lymphocyte cells, and classifying the corresponding TLS region as one of a first TLS maturation state, a second TLS maturation state, and a third TLS maturation state by processing each set of TLS features using a TLS classification model (350).

The invention belongs to the technical field of blood disease diagnosis, and provides a noninvasive screening method for acute B lymphocytic leukemia (B-ALL) based on a peripheral blood CD3 + CD19 + double positive cell subset, which comprises the following steps: detecting the proportion of CD3 + CD19 + double positive cells in peripheral blood through flow cytometry, and comparing the proportion with a proportion threshold in a positive judgment standard for judgment; when the detection result is greater than or equal to 0.20%, judging that the sample is positive; cD3 + CD19 + double positive cells exist in B-ALL peripheral blood, the detection rate of B-ALL peripheral blood in peripheral blood of healthy people and other types of leukemia patients is extremely low, and the B-ALL has high specificity; compared with bone marrow puncture and other invasive diagnosis methods, the non-invasive primary screening of B-ALL is realized, and the problem of insufficient specificity of the existing non-invasive detection technology is overcome; the kit is suitable for early screening of children B-ALL, dynamic monitoring of chemotherapy curative effect and prognosis evaluation, and has important clinical application value.

Provided herein are compositions and methods for treating cancer using modified TILs, the modified TILs comprising one or more immunomodulatory agents (e.g., cytokines) associated with their cell surface. The immunomodulatory agents associated with the TILs provide a local immunostimulatory effect that can advantageously enhance TIL survival, proliferation, and / or antitumor activity in a patient recipient. Thus, the compositions and methods disclosed herein provide effective cancer therapy.

The present invention belongs to the field of cell culture technology, and specifically relates to a method for culturing high-purity NK cells, which includes: separating mononuclear cells from blood by density gradient centrifugation; using culture bottles for coating, using lymphocyte serum-free medium for mononuclear cells, adding GMP-grade recombinant proteins or humanized antibodies and blood sample serum for 20 days; after the cell culture is completed, centrifugation is performed to collect cells, NK cells are washed 3 times with saline, and then the cells are resuspended with saline and fixed to 200 ml after adding 5% human serum albumin. The present invention establishes a high-purity cell culture technology that meets GMP standards, which is not only applicable to peripheral blood but also to the culture of umbilical cord blood NK. Only 50 ml of peripheral blood and umbilical cord blood samples need to be collected, and all operations are completed under GMP conditions. The number of cells cultured by the 8L system for about 20 days can also reach the clinical treatment application standard.